North American cancer monoclonal antibodies market is estimated to grow at a CAGR of 9.6% during the forecast period. The increasing prevalence of cancer and increasing research on monoclonal antibodies are some pivotal factors driving market growth. As per the Centers for Disease Control and Prevention (CDC), the number of new cancer incidences in the US is expected to grow from nearly 1.5 million annually in 2010 to 1.9 million annually in 2020. This results in an increasing demand for monoclonal antibody drugs that act as a targeted therapy to destroy cancer cells. Monoclonal antibodies served as one of the established therapeutic strategies for both solid tumors and hematologic malignancies. It is a type of immunotherapy that stimulates the immune system of cancer patients and works to discover and attack cancerous cells.

Request a free sample of our report on North American cancer monoclonal Antibodies Market: https://www.omrglobal.com/request-sample/north-american-cancer-monoclonal-antibodies-market

North American cancer monoclonal antibodies market is segmented based on type and application. Based on type, the market is classified into naked, conjugated, and others. Based on the application, the market is classified into breast cancer, liver cancer, blood cancer, brain cancer, colorectal cancer, and others. Monoclonal antibodies are expected to find significant application in breast cancer. Kadcyla, (also referred to as TDM-1) targets the HER2 protein like Herceptin. These therapies act against the HER2 protein as this protein is found in massive amounts on certain kinds of breast cancer cells. The therapy is utilized for the treatment of HER2-positive breast cancer. Most often monoclonal antibodies are combined with additional cancer-fighting drugs, including chemotherapy. In the US, breast cancer accounted for the largest share of 11.0% or 234,087 in new cancer incidences in 2018, which is contributing to the adoption of monoclonal antibodies therapy in the region.

A full report of North American cancer monoclonal Antibodies Market is available at: https://www.omrglobal.com/industry-reports/north-american-cancer-monoclonal-antibodies-market

North American Cancer Monoclonal Antibodies Market Segmentation

By Type

Naked

Conjugated

Others (Bispecific)

By Application

Breast Cancer

Liver Cancer

Blood Cancer

Brain Cancer

Colorectal Cancer

Others

Regional Analysis

United States

Canada

Company Profiles

AbbVie Inc.

Amgen Inc.

AytuBioScience, Inc.

Biocon Ltd.

Bristol Myers Squibb Co.

Eli Lilly and Co.

F. Hoffman La-Roche AG

Gilead Sciences, Inc.

Johnson & Johnson Services, Inc.

Merck & Co., Inc.

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/north-american-cancer-monoclonal-antibodies-market

About us:

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: [email protected]

Contact no: +91 780-304-0404